LIGAND PHARMACEUTICALS INC Insider Trading for January 2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in LIGAND PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in LIGAND PHARMACEUTICALS INC for January 2021.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 21.92 | 30,000 | 657,600 | 65,616 | |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 14.47 | 40,000 | 578,800 | 69,000 | |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 14.47 | 50,000 | 723,500 | 109,000 | |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 21.92 | 30,000 | 657,600 | 273,422 | 243.4 K to 273.4 K (+12.32 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 182.00 | 40,000 | 7,280,000 | 243,422 | 283.4 K to 243.4 K (-14.11 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 14.47 | 40,000 | 578,800 | 283,422 | 243.4 K to 283.4 K (+16.43 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 156.01 | 4,596 | 717,022 | 243,422 | 248 K to 243.4 K (-1.85 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 9,607 | 0 | 248,018 | 238.4 K to 248 K (+4.03 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 156.01 | 2,845 | 443,848 | 238,411 | 241.3 K to 238.4 K (-1.18 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 5,946 | 0 | 241,256 | 235.3 K to 241.3 K (+2.53 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 159.00 | 50,000 | 7,950,000 | 235,310 | 285.3 K to 235.3 K (-17.52 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 14.47 | 50,000 | 723,500 | 285,310 | 235.3 K to 285.3 K (+21.25 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Payment of Exercise | F | 156.01 | 2,272 | 354,455 | 160,603 | 162.9 K to 160.6 K (-1.39 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Grant | A | 0.00 | 5,604 | 0 | 162,875 | 157.3 K to 162.9 K (+3.56 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Payment of Exercise | F | 156.01 | 1,053 | 164,279 | 157,271 | 158.3 K to 157.3 K (-0.67 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Grant | A | 0.00 | 2,911 | 0 | 158,324 | 155.4 K to 158.3 K (+1.87 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Payment of Exercise | F | 156.01 | 1,440 | 224,654 | 30,933 | 32.4 K to 30.9 K (-4.45 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Grant | A | 0.00 | 4,803 | 0 | 32,373 | 27.6 K to 32.4 K (+17.42 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Payment of Exercise | F | 156.01 | 671 | 104,683 | 27,570 | 28.2 K to 27.6 K (-2.38 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Grant | A | 0.00 | 2,305 | 0 | 28,241 | 25.9 K to 28.2 K (+8.89 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Payment of Exercise | F | 156.01 | 830 | 129,488 | 43,512 | 44.3 K to 43.5 K (-1.87 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Grant | A | 0.00 | 2,401 | 0 | 44,342 | 41.9 K to 44.3 K (+5.72 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Payment of Exercise | F | 156.10 | 509 | 79,455 | 41,941 | 42.5 K to 41.9 K (-1.20 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Grant | A | 0.00 | 1,335 | 0 | 42,450 | 41.1 K to 42.5 K (+3.25 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Option Exercise | M | 113.50 | 2,456 | 278,756 | 0 | |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Buy | M | 113.50 | 2,456 | 278,756 | 52,761 | 50.3 K to 52.8 K (+4.88 %) |
| Jan 05 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | J | 84.53 | 223 | 18,851 | 235,310 | 235.1 K to 235.3 K (+0.09 %) |